日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Effect of Finerenone on Morbidity and Mortality in CKD

非奈利酮对慢性肾脏病患者发病率和死亡率的影响

Ostrominski, John W; Filippatos, Gerasimos; Claggett, Brian L; Miao, Zi Michael; Desai, Akshay S; Jhund, Pardeep S; Henderson, Alasdair; Rohwedder, Katja; Brinker, Meike D; Scalise, Andrea; Schloemer, Patrick; Lam, Carolyn S P; Senni, Michele; Shah, Sanjiv J; Voors, Adriaan A; Zannad, Faiez; Rossing, Peter; Ruilope, Luis M; Anker, Stefan D; Pitt, Bertram; Agarwal, Rajiv; McMurray, John J V; Solomon, Scott D; Vaduganathan, Muthiah

Finerenone in People with CKD, Type 2 Diabetes, and History of Nephrectomy

非奈利酮在慢性肾病、2型糖尿病和肾切除史患者中的应用

Munoz Mendoza, Jair; Weir, Matthew R; Anker, Stefan D; Filippatos, Gerasimos; Rossing, Peter; Ahlers, Christiane; Brinker, Meike; Fatoba, Samuel T; Horvat-Broecker, Andrea; Rohwedder, Katja; Fornoni, Alessia

Heart failure evidence update 2026

2026年心力衰竭证据更新

Liori, Sotiria; Kapelios, Chris J; Savarese, Gianluigi; Filippatos, Gerasimos

Effects of SGLT2 inhibitors across the spectrum of albuminuria in cardiovascular-kidney-metabolic conditions: A pooled analysis of randomised trials

SGLT2抑制剂对心血管-肾脏-代谢性疾病中不同程度蛋白尿的影响:随机试验的汇总分析

Ferreira, João Pedro; Marques, Pedro; Anker, Stefan D; Butler, Javed; Filippatos, Gerasimos; Sharma, Abhinav; Vasques-Nóvoa, Francisco; Mendonça, Luís; Neves, João Sérgio; Packer, Milton; Zannad, Faiez

A FIDELITY Analysis on Finerenone With SGLT-2i and GLP-1RA in CKD

一项关于非奈利酮联合SGLT-2抑制剂和GLP-1受体激动剂治疗慢性肾脏病的FIDELITY分析

Singh, Ajay K; Anker, Stefan D; Pitt, Bertram; Rossing, Peter; Ruilope, Luis M; Ahlers, Christiane; Farag, Youssef M K; Lambelet, Marc; Brinker, Meike D; Rohwedder, Katja; Filippatos, Gerasimos

Empagliflozin in Heart Failure and Previous Coronary Revascularization: Insights From EMPEROR-Pooled

恩格列净治疗心力衰竭和既往冠状动脉血运重建:来自 EMPEROR 汇总研究的启示

Dhingra, Nitish K; Butler, Javed; Anker, Stefan D; Ferreira, Joao Pedro; Filippatos, Gerasimos; Pfarr, Egon; Gasior, Tomasz; Nordaby, Matias; Brueckmann, Martina; Pocock, Stuart J; Zannad, Faiez; Packer, Milton; Verma, Subodh

Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction: the EMPEROR-Preserved trial

恩格列净治疗难治性高血压和射血分数保留型心力衰竭:EMPEROR-Preserved 试验

Böhm, Michael; Butler, Javed; Coats, Andrew; Lauder, Lucas; Mahfoud, Felix; Filippatos, Gerasimos; Ferreira, João Pedro; Pocock, Stuart J; Brueckmann, Martina; Hauske, Sibylle J; Schueler, Elke; Wanner, Christoph; Verma, Subodh; Zannad, Faiez; Packer, Milton; Anker, Stefan D

Finerenone and Atrial Fibrillation in Heart Failure: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial

非奈利酮与心力衰竭患者的房颤:FINEARTS-HF随机临床试验的二次分析

Matsumoto, Shingo; Henderson, Alasdair D; Jhund, Pardeep S; Bauersachs, Johann; Chioncel, Ovidiu; Claggett, Brian L; Comin-Colet, Josep; Desai, Akshay S; Filippatos, Gerasimos; Lam, Carolyn S P; Pitt, Bertram; Scheerer, Markus Florian; Lay-Flurrie, James; Amarante, Flaviana; Brinker, Meike; Schou, Morten; Senni, Michele; Shah, Sanjiv J; Voors, Adriaan A; Zannad, Faiez; Zieroth, Shelley; Vaduganathan, Muthiah; Solomon, Scott D; McMurray, John J V

End-organ protective effect of serelaxin in patients hospitalized for heart failure: Results of the biomarker substudy of Relaxin in Acute Heart Failure-2 (RELAX-AHF-2)

舒拉辛对因心力衰竭住院患者的终末器官保护作用:急性心力衰竭舒拉辛-2 (RELAX-AHF-2) 生物标志物子研究的结果

Voors, Adriaan A; Metra, Marco; Postmus, Douwe; Greenberg, Barry H; Cotter, Gadi; Davison, Beth A; Beldhuis, Iris E; Felker, G Michael; Filippatos, Gerasimos; Pang, Peter S; Ponikowski, Piotr; Gimpelewicz, Claudio; Teerlink, John R

Association of clonal haematopoiesis with heart failure incidence and outcomes: A systematic review and meta-analysis

克隆性造血与心力衰竭发生率和预后的关系:系统评价和荟萃分析

Karakasis, Paschalis; Lefkou, Eleftheria; Pamporis, Konstantinos; Farmakis, Dimitrios; Patoulias, Dimitrios; Antoniadis, Antonios P; Heymans, Stephane; Filippatos, Gerasimos; Fragakis, Nikolaos